# Eltrombopag Olamine in Increasing Platelet Counts in Patients Undergoing Transplant

> **NCT01927731** · PHASE2 · COMPLETED · sponsor: **M.D. Anderson Cancer Center** · enrollment: 48 (actual)

## Conditions studied

- Bone Marrow Transplantation Recipient
- Cord Blood Transplant Recipient
- Hematopoietic Cell Transplantation Recipient

## Interventions

- **DRUG:** Eltrombopag Olamine
- **OTHER:** Laboratory Biomarker Analysis

## Key facts

- **NCT ID:** NCT01927731
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-10-14
- **Primary completion:** 2023-06-06
- **Final completion:** 2023-06-06
- **Target enrollment:** 48 (ACTUAL)
- **Last updated:** 2024-04-23

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01927731

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01927731, "Eltrombopag Olamine in Increasing Platelet Counts in Patients Undergoing Transplant". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01927731. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*